Danshensu for Myocardial Ischemic Injury: Preclinical Evidence and Novel Methodology of Quality Assessment Tool

Danshensu for Myocardial Ischemic Injury: Preclinical Evidence and Novel Methodology of Quality Assessment Tool

Background: Danshensu (DSS) possesses unique bioactivity on the cardiovascular system. However, there is a lack of systematical summary of DSS for acute myocardial ischemia injury and no quality assessment tool for the systematical review of cell experiments. Here, we aimed to assess the preclinical...

Full description

Bibliographic Details
Main Authors: Xiao-yi Bao, Qun Zheng, Qiang Tong, Peng-chong Zhu, Zhuang Zhuang, Guo-qing Zheng, Yan Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-12-01
Series:Frontiers in Pharmacology
Subjects:
danshensu
infarct size
ischemia
reperfusion
meta-analysis
methodology
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2018.01445/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2018.01445/full

Similar Items